Using AI to Match Patients With Clinical Trials in Minutes
Since 2020, the number of clinical trials worldwide has increased by more than 60%, from 325,000...
Read More
Imfinzi – Lung Cancer – AZ Imfinzi Poseidon SEP Display Banners HCP Wallboard Extension- 2023 – 57786
Alternatives to ERBB2-Target Therapy May Offer Better Survival for NSCLC
C ompared with other oncogenic drivers, ERBB2 (also known as HER2) tends to have poor prognosis in patients with advanced NSCLC, according to researchers, who noted that the treatment for ERBB2-altered NSCLC has been studied for...
Read MoreBlood-Based Biomarker & PLCO Risk Model Detect Lethal Lung Cancer
A blood-based biomarker panel combined with the Prostate, Lung, Colorectal, and Ovarian (PLCO) risk model (PLCOm2012) can identify individuals at high risk for lethal lung cancer, according to a study published in the Journal of...
Read MoreImmune Checkpoint Inhibitors Are Safe & Effective for Older Patients With NSCLC
For older patients with advanced NSCLC, treatment with immune checkpoint inhibitors (ICIs) may be a safe and effective option, according to a study published in Respiratory Investigation. Researchers conducted a retrospective...
Read More
Which Specialties Offer the Highest Compensation for Physicians?
Choosing a specialty can be a daunting task for physicians. According to an article published in...
Read More